Merck Serono to analyze biomarkers at Chinese R&D site; New marker spots chemo-resistant cases of ovarian cancer;

> Merck Serono plans to put a Chinese R&D operation in the CRO Pharmaron's facility in Beijing, where Merck Serono plans to analyze biomarkers for research of personalized therapies. Report

> Researchers at the Moffitt Cancer Center are studying a pathway called BCL2 agonist of cell death, or BAD, that could be used as a biomarker for aggressive forms of ovarian cancer that are resistant to chemotherapy. Item

> The National Parkinson Foundation said it is funding, among other projects, work at Northwestern University on a smartphone app that could be used to monitor "gait disturbance" in Parkinson's patients, recording a biomarker that could be used to track progression of the disease. Release

> Nature Nanotechnology has a new article about the promise of nanopore sensors in analyzing nucleic acids, making the tools useful in biomarker discovery. Article

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.